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A 63-year-old asymptomatic woman with cured Hodgkin diseases presented for restaging. The chest
computed tomography showed a mass at the right side of the upper mediastinum. The benignity and the
origin of the tissue were unknown. First, we performed a bronchoscopy-guided biopsy but without success. In
the next step, we initiated radionuclide imaging with technetium-99m pertechnetate (Tc-99m) and radioiodine
(I-123). Low uptake of Tc-99m and intense accumulation of I-123 after 2 and 24 h to the mediastinal mass
suggested that the mass was a mediastinal goiter. Based on iodine uptake and the fact that our patient had no
symptoms of tracheal compression, we decide to go for a radioiodine therapy.
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A
63-year-old asymptomatic woman with cured
Hodgkin diseases presented in our hospital for
restaging.
The physical examination and the laboratory tests were
without pathological findings. The chest computed tomo-
graphy (CT) showed a 544475 mm mass at the right
side of the upper mediastinum (Fig. 1A). The benignity
and the origin of the tissue were still unknown. Therefore,
after the CT, we performed a bronchoscopy with biopsy
because it was very difficult radiologically to differentiate,
for example, lymphoma (relapse) from other mediastinal
tumors such as goiter. The histopathological results were
unfortunately without success. Fine-needle biopsies are
often difficult because of the inaccessibility of the mass or
of the unreliability of the results. In our case, a broncho-
scopy-guided rebiopsy aswell a fine-needle aspiration was
refused by the patient. In the next diagnostic step, we
initiated radionuclide imaging with technetium-99m per-
technetate (Tc-99m; Fig. 1B) and radioiodine (I-123;
Fig. 1C, D). Low uptake of Tc-99m and intense accumu-
lation of I-123 after 2 h (Fig. 1C) and 24 h (Fig. 1D) to the
mediastinal mass suggested that the paratracheal mass
was a mediastinal goiter. The relatively expensive tracer I-
123 offers the following advantages compared with Tc-
99m: I-123 has the higher gamma energy of 159 keV
instead of 141 keVand has higher uptake into the thyroid,
which is relevant for the penetration of the gamma
emitters through the chest wall. The I-123 scan after
24 h shows organification of iodine, which is specific for
thyroid tissue. Tc-99m uptake stands for trapping of an
iodine analog in the early phase, but Tc-99m is not used
for the synthesis of thyroid hormone. Thyroid nodules,
which accumulate Tc-99m, but the late I-123 scans are
iodine negative, are called ‘trapping only nodules.’ In such
a constellation, the dignity of the tissue remains unclear,
and patients are not qualified for radioiodine therapy.
Based on I-123 uptake and the fact that our patient had
no symptoms of tracheal stenosis such as stridor, we
decide for a radioiodine therapy. The post-therapeutic
I-131 scans 5 days after I-131 application show the
organification of I-131 (E). One year later, magnetic
resonance imaging presented goiter shrinkage without
narrowing of the trachea (F).
Learning points
1) Mediastinal goiters are the most frequent masses in
the superior mediastinum (13).
2) The CT and radionuclide imaging can suggest or
make the diagnosis in most cases.
3) In treatment, the radioactive I-131 therapy has been
effectively used to reduce the size of intrathoracic
goiters.
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Fig. 1. (A) Contrast-enhanced CT demonstrates a homogeneous mass at the right side of the mediastinum (arrow). (B) Thyroid
scintigraphy with 75 MBq Tc-99m pertechnetate. The scanning showed only marginal activity throughout the mediastinal mass
(arrow). (C) Scintigraphy with 10 MBq I-123 2 h post-injection. (D) Image 24 h later. The late accumulation of I-123 at the right
thyroid lobe and the mediastinal mass are the direct evidence that both areas are composed of a thyroid hormone-producing
tissue. (E) Image 5 days after I-131 therapy. (F) Magnetic Resonance Imaging (MRI) 1 year after radioiodine therapy.
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